MetaCap

Beam Therapeutics Inc. (BEAM)

NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

20.90-0.04 (-0.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BEAM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.87
52-week range
20.44 – 38.26
Day range
20.54 – 22.10
Volume / Avg
3.88M / 2.04M
Beta
—

52-week range

$20.44$38.26

BEAM stock today

Shares of Beam Therapeutics (BEAM) finished lower on Nov 20 at $20.90, a drop of 0.19% or $0.04 per share, versus the S&P 500's 3.70% decline. Shares are 45.4% below their 52-week high of $38.26, set on Jul 7, 2026 and 2.3% above the 52-week low of $20.44, near the bottom of the past year's range. BEAM is down 24.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.9%.

Beam Therapeutics has posted a net loss over the last twelve months (EPS of -$0.87), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Beam Therapeutics

Company profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. John M. Evans M.B.A.
Headquarters
Cambridge, MA
Employees
557
IPO year
2020
Website
beamtx.com

Financial highlights

Full financials

In fiscal 2025, Beam Therapeutics generated $139.7 million in revenue, up 120.0% from fiscal 2024. Beam Therapeutics reported a net loss of $80.0 million, compared with a loss of $376.7 million a year earlier. Operating margin was -274.6%.

Beam Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$139.74M$63.52M$377.71M$60.92M$51.84M
Growth+120.01%-83.18%+520.01%+17.51%+215916.67%
Net income$-79.99M$-376.74M$-132.53M$-289.09M$-370.64M
EPS (diluted)$-0.81$-4.58$-1.72$-4.13$-5.77

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$49.85+138.52%

  • Strong buy 1
  • Buy 12
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $26.00High $80.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-1.28 vs $-1.17
Surprise
-9.40%

BEAM news

All BEAM news

Beam Therapeutics peers

Health Care sector
BEAM peer companies
CompanyPrice% ChgMarket capCompare
BCRXBioCryst Pharmaceuticals Inc.7.22-1.37%$1.86Bvs BEAM
COAGHemab Therapeutics Holdings Inc.39.29-1.43%$1.84Bvs BEAM
REPLReplimune Group Inc.19.07-0.83%$1.81Bvs BEAM
LYCALycia Therapeutics Inc.33.07+4.09%$1.72Bvs BEAM
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs BEAM
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs BEAM
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs BEAM
ALVOAlvotech4.12-3.96%$1.47Bvs BEAM

Indexes, lists and sector

Beam Therapeutics stock FAQ

What is Beam Therapeutics's stock price today?

BEAM last traded at $20.90 as of Nov 20, 4:00 PM EST, down 0.19% on the day. Prices are delayed at least 15 minutes.

Who is Beam Therapeutics's CEO?

Mr. John M. Evans M.B.A. is the chief executive officer of Beam Therapeutics Inc., which has about 557 employees.

What is the BEAM 52-week high?

The 52-week high for BEAM is $38.26 and the 52-week low is $20.44. The stock is currently 45.4% below its high.

Compare BEAM